# The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01490125** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 247 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** QVA149
- **DRUG:** Tiotropium
- **DRUG:** Placebo to QVA149
- **DRUG:** Placebo to tiotropium
- **DRUG:** Salbutamol/albuterol

## Key facts

- **NCT ID:** NCT01490125
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2013-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01490125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01490125, "The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01490125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*